)
Visual
earnings real time
Nykode Therapeutics (NYKD) investor relations material
Nykode Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary24 Nov, 2025
Executive summary
Focused on three core assets: Abi-suva (lead HPV16-driven cancer immunotherapy), VB10.NEO (individualized neoantigen therapy), and the ASIT/tolerance platform for autoimmune diseases and allergies.
Advanced Abi-suva into a randomized controlled phase II trial (Abili-T/Ability trial) for first-line head and neck cancer, with protocol submitted to UK authorities and EMA submission planned.
Strengthened proprietary position for VB10.NEO with a new US patent for the NeoSELECT platform and presented validating clinical and preclinical data.
Demonstrated long-lasting, multi-compartment immune modulation with the tolerance/ASIT platform, showing efficacy in multiple autoimmune disease models.
Achieved key milestones: protocol submission for Abili-T trial, supply agreement for pembrolizumab, and new U.S. patent for NeoSELECT platform.
Financial highlights
Q3 2025 revenue and other income: USD 0.1 million (NOK 118,000), down from USD 0.7 million (NOK 665,000) in Q3 2024, mainly due to reduced revenue from Genentech and Regeneron.
Operating expenses reduced to USD 6.4 million (NOK 6.4 million) from USD 15.6 million (NOK 15.6 million) year-over-year, reflecting organizational streamlining and lower clinical activity.
Net loss of USD 3.7 million (NOK 3.7 million), improved from USD 9.7 million (NOK 9.7 million) in Q3 2024.
Cash position of USD 63.9 million (NOK 64 million) at quarter-end; equity of USD 99 million with a 94% equity ratio.
Dividend of USD 32.3 million paid in Q2 2025.
Outlook and guidance
Cash runway extends into 2028, potentially 2029 pending a positive tax case outcome.
Interim data from the ongoing C-03/CO3 trial expected in the first half of 2026; first interim data from the Abili-T/Ability trial anticipated in 2027.
Focus on leveraging peer data readouts in the individualized neoantigen therapy field over the next 15 months.
Abili-T first patient dosing target
VB10.NEO: How will peer readouts shape strategy?
Tolerance platform: Broadest immune response effect?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Nykode Therapeutics earnings date
Q4 202526 Feb, 2026
Next Nykode Therapeutics earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company based in Oslo, Norway. The company focuses on the discovery and development of novel vaccines and immunotherapies, primarily targeting cancer and infectious diseases. Nykode leverages its proprietary modular vaccine technology, which directs antigens to antigen-presenting cells, aiming to induce strong and long-lasting immune responses. Its leading product candidates include VB10.16, a therapeutic vaccine in development for human papillomavirus (HPV)-related cancers, and VB10.NEO, a cancer neoantigen vaccine, which is in clinical trials for several types of advanced tumors. The company is headquartered in Oslo, Norway, and its shares are listed on the Oslo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage